The final, formatted version of the article will be published soon.
EDITORIAL article
Front. Immunol.
Sec. Cancer Immunity and Immunotherapy
Volume 15 - 2024 |
doi: 10.3389/fimmu.2024.1491982
This article is part of the Research Topic Treating Solid Organ Diseases with Innovative Chimeric-Antigen Receptor T-cells: Current indications, progress, limitations and potential strategies View all 6 articles
Treating Solid Organ Diseases with Innovative Chimeric-Antigen Receptor T-cells: Current indications, progress, limitations and potential strategies
Provisionally accepted- 1 Consultant, New York, United States
- 2 Viridian Therapeutics, Inc., Waltham, Massachusetts, United States
- 3 Orbital Therapeutics, Inc., Cambridge, Massachusetts, United States
- 4 Akamis Bio, Cambridge, United States
Keywords: CAR- T cells, CAAR T cell, Solid tumor, anti-tumor activities, Persistence, Adhesion, Tumor infiltration, therapeutic efficacy
Received: 05 Sep 2024; Accepted: 09 Sep 2024.
Copyright: © 2024 Quackenbush, Vijayaraghavan, Ozay and Ji. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence:
Elizabeth Quackenbush, Consultant, New York, United States
Rui-Ru Ji, Akamis Bio, Cambridge, United States
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.